Wuhan YZY Biopharma Co., Ltd. (HKG:2496)
Hong Kong
· Delayed Price · Currency is HKD 5.70
0.00 (0.00%)
At close: Mar 10, 2026
Wuhan YZY Biopharma Company Description
Wuhan YZY Biopharma Co., Ltd., a biotechnology company, develops bispecific antibody-based therapies for the treatment of cancer, cancer-related complications, and age-related ophthalmologic diseases.
The company develops various product candidates for the treatment of malignant ascites, malignant pleural effusion, solid tumors, pancreatic cancer, hepatocellular carcinoma, and other advanced solid tumors; wAMD, DME, and other ocular neovascularization-related diseases; hemophilia; and inflammatory bowel diseases.
Wuhan YZY Biopharma Co., Ltd. was founded in 2010 and is headquartered in Wuhan, China.
Wuhan YZY Biopharma Co., Ltd.
| Country | China |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 106 |
| CEO | Pengfei Zhou |
Contact Details
Address: Biolake, C2-1 Wuhan, 430075 China | |
| Phone | 86 27 8266 8988 |
| Website | yzybio.com |
Stock Details
| Ticker Symbol | 2496 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE1000063C4 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Pengfei Zhou / Ph.D., M.D. | Chairman of the Board and Chief Executive Officer |
| Zhicheng Wen | Executive Director |
| Dr. Jizu Yi | Senior Vice President of Quality |
| Jianhua Zheng | Senior Manager of Strategic Development Department and Joint Company Secretary |
| Tin Yun Lai | Joint Company Secretary |